Last updated: April 21, 2024
Sponsor: Think Healthy Group, Inc.
Overall Status: Completed
Phase
N/A
Condition
N/ATreatment
Magnesium citrate or magnesium oxide
Picometer-ionic form of magnesium chloride
Placebo
Clinical Study ID
NCT04139928
THG-IU-MG-1
Ages 18-65 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age 18- 65 years
- Body mass index 18 to 35 kg/m2 , body weight ≥ 110 pounds or 50 kg
- All race/ethnicities and both sexes, are eligible.
- Normal blood pressure (BP) ≤ 120/80 mm Hg.
Exclusion
Exclusion Criteria:
- Participant has a diagnosis of hypertension, prehypertension, diabetes, cardiovascularor other chronic disease (e.g., cancer).
- Participant has a diagnosis of hypermagnesemia (defined as a serum concentration of > 22.8 mg/L of Magnesium) (4).
- Participant is already taking magnesium supplementation prior to the study or takingmedications that interfere with magnesium metabolism, we are providing examples in anappendix.
- Participant has concurrent use of magnesium supplements and/or other nutrientsupplements that interfere with magnesium absorption (e.g., calcium supplements)within 2-wk prior the first treatment or during the course of this study.
- Participant has gastrointestinal disease, hepatitis, anemia, or hepatic enzymeabnormalities.
- Women subjects are currently pregnant or trying to become pregnant.
- Participant has a history of hospitalization for acute illness in the previous 1month.
- Participants who do not speak English or are unable to read or fail to comprehend theinformed consent form.
- Participants fail to complete the full medical questionnaire reviewed with them duringthe initial phone call (whether it be because they refuse to answer or because theydon't know/understand the questions).
- Participants who have a body weight less than 110lbs (or 50kg).
- Participants who have donated blood within the last month, or are currently givingblood for other clinical or research purposes.
- Participants who smoke and/or use tobacco products.
Study Design
Total Participants: 17
Treatment Group(s): 3
Primary Treatment: Magnesium citrate or magnesium oxide
Phase:
Study Start date:
August 01, 2018
Estimated Completion Date:
April 28, 2020
Connect with a study center
Indiana University
Bloomington, Indiana 47405
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.